Sign inJoin free

Watch / CEOs & MDs

Actinogen takes a step towards treating depression

23 Apr 20245:24

Actinogen takes a step towards treating depression

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key Topics:

  • Trial of Zanten for Major Depressive Disorder

  • Development and action mechanism of said drug

  • Looking towards FDA approval and future strategic partnerships

Steven Gourlay, CEO of Actinogen Medical (ACW), discusses their trial investigating treatments for Major Depressive Disorder (MDD) in an enlightening conversation. Gourlay articulates the uniqueness of this trial, highlighting that their drug inhibits the synthesis of the stress hormone cortisol in the brain, while leaving the normal stress response intact in other parts of the body. Furthermore, he reveals the drug, Zanten, could improve the cognitive impairment that is often associated with depression, and does not often respond to conventional antidepressants.

Addressing concerns about conventional antidepressants, Gourlay discusses the development of a once-a-day low-dose oral pill, asserting its favorable safety profile and its effects on working memory. He asserts that it's designed to kick in relatively quickly, within 2 to 4 weeks. The results from the Zanten trial are due to be released in early Q3. Gourlay also reveals plans to widen the trial to address other cognitive disorders such as Alzheimer's, and has high hopes that Zanten may slow the progression of the Alzheimer's disease.

Steven concludes the conversation by spotlighting future plans for Actinogen Medical. The company is aiming to achieve FDA approval, and currently all their trials, manufacturing, and studies are supervised by the FDA. He also outlines the existing partnership with UK regulator, MHRA, and expresses optimism about the firm's future, with an anticipation of promising pharmaceutical partnerships.

Find the full unedited transcript of this interview below:

The Aussie Biotech Actinogen Medical is pushing ahead with its research in the neuropsychiatric field. Enrollment is now complete in its phase two clinical trial for major depressive disorder, or MDD. For more details on this Actinogen Medical's Chief Executive Officer Steven Gourlay joins me now. Hi, Steven. Just tell us about this trial. I believe something like 167 patients.

0:25

Yes. Thanks. And thanks for having me. Um, yes. We're very pleased to have fully enrolled the trial. We. The target was originally 160 patients, and the enthusiasm at the site led us to a few extra patients, which is totally okay in the world of clinical trials. And what's important about this trial is that it's quite unique. First of all, our drug is a unique drug that inhibits the synthesis of the stress hormone cortisol in the brain, but leaves your normal stress intact and stress response intact in the rest of the body. And what it is designed to do is improve the cognitive impairment, or foggy thinking that patients with depression often have and often doesn't respond to normal conventional antidepressants. And so we believe our drug, Zanten, may well be able to treat both the foggy thinking and depression itself, and we'll have results in just a few months in early Q3. And I guess, Stephen, just tell us how it's taken. Is it an oral therapy? And I guess also in terms of how long patients might need to take it before it kicks in?

1:25

Because a lot of concern sometimes about antidepressants is they take too long to kick in. And that is the fact that that actually just ends up, I guess, making the person even sicker.

1:37

Yeah. Great question. Uh, you obviously know a little bit about this. So, um, yes. And common antidepressants that are used have a risk of suicide in the first few weeks of being taken. They often take several weeks to work or longer. And so we have a once a day low dose oral pill. It has a very good safety profile, with more than 350 people treated at this stage. And it reacts relatively quickly. We know from, uh, cognitively normal or, you know, people with normal thinking who've been in volunteer trials that the drug can improve attention and working memory in just 2 to 4 weeks. So it actually has quite, quite fast action. And we should be able to see that in the results of this trial in patients with depression. And if it is helping, as you say, with the cognitive aspect and the foggy brain memory, does that then help as well, in terms of some of the other diseases we see like Alzheimer's? I know you're in that space too.

2:31

Yes. We have a trial of 220 patients with mild to moderate Alzheimer's ongoing in Australia, which will soon expand. We hope, to the US that trial. We've actually done some work in Alzheimer's before and found that in biomarker positive patients with a biomarker indicating progressive Alzheimer's disease, we have a big treatment effect. And this is like a pilot study if you like. So yes, we do believe this drug will have potential to not only treat the cognitive impairment that comes with Alzheimer's, but also, we hope, slow progression of the disease. It's also suitable for other diseases, such as schizophrenia, where cognitive impairment is a major problem, and also the other dementias as well. So it has quite broad applicability as we go forward. Stephen, just tell us, I guess, what the next steps are, because I assume at some point you want to get FDA approval.

3:22

Yes. So we operate under a US IND or Investigational New drug application for all of our program. So all of our manufacturing, which we've scaled up successfully, or and all of our animal studies and our human studies, all of those are supervised by the FDA. So as the US continues to be the world's largest pharmaceutical market, we certainly keep a close eye and seek advice from the agency on a regular basis. So we'll continue to do that. We have a great relationship with the FDA. We were recently granted a type of breakthrough or special regulatory status by the UK regulator, MHRA, who recognised that this is an animal program for Alzheimer's disease could be a really big, important new development and that gives us a leg up in the UK with bringing the program forward and getting it approved. So, uh, we're very excited about the future. We're sort of at a transformational point in the company's history, uh, having two major phase two studies with the depression trial reading out in just a

4:22

few months and tell us, I guess, where you're at in terms of further funding and R&D, too.

4:29

Yes. So, uh, R&D cost money and and we we're fortunate that we actually are able to do our trials much more efficiently based in Australia, much cheaper than an American company. Uh, could do it. Uh, we benefit from the Australian R&D tax incentive. And, um, at the last, uh, reporting period at the end of December, we had more than 11 million in the bank. Uh, we're burning 4 to 5 million a quarter. Uh, and we have a number of different funding alternatives, uh, available to us, including, importantly, hopefully, a lot of incoming strategic pharmaceutical company interest with a positive depression study in the very near future. So a financing point of view. We're in good shape. Uh, but we do look forward to forming valuable pharmaceutical partnerships as a way to bring these programs forward faster and get them approved even faster for patients.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy